BioCentury | Jan 11, 2017
Distillery Techniques

Drug platforms

...region of a mutant, thermostabilized version of CCR9 complexed with the allosteric CCR9 antagonist Traficet-EN vercirnon...
...testing of allosteric inhibitors of other G protein-coupled chemokine receptors. ChemoCentryx Inc. has Traficet-EN (vercirnon; GSK1605786...
...2016 doi:10.1038/nature20605 CONTACT: Tracy Handel, University of California San Diego, La Jolla, Calif. email: thandel@ucsd.edu Hongjiang Li Traficet-EN Heptares...
BioCentury | Apr 21, 2016
Distillery Therapeutics

Therapeutics: CC chemokine receptor 9 (CCR9; CDw199)

...the compounds in additional models of colitis. ChemoCentryx Inc. has the CCR9 antagonist Traficet-EN (vercirnon; GSK1605786...
BioCentury | Nov 3, 2014
Clinical News

Vercirnon: Phase III data

...who received 500 mg vercirnon once daily and 69% of patients who received 500 mg vercirnon...
...at week 12 was 25% in the once-daily vercirnon arm and 33% in the twice-daily vercirnon...
...ChemoCentryx Inc. (NASDAQ:CCXI), Mountain View, Calif. Product: Vercirnon ( Traficet-EN ) ( GSK1605786 ) (formerly CCX282-B...
BioCentury | Dec 9, 2013
Company News

ChemoCentryx, GlaxoSmithKline deal

...companies share no remaining partnered products. In September, GSK returned to ChemoCentryx all rights to vercirnon...
BioCentury | Dec 4, 2013
Company News

GSK returns remaining ChemoCentryx programs

...companies share no remaining partnered products. In September, GSK returned to ChemoCentryx all rights to vercirnon...
BioCentury | Oct 7, 2013
Finance

3Q Stock Wrap-Up: Make it a double

...in patients treated with Revlimid compared to chlorambucil ChemoCentryx Inc. (NASDAQ:CCXI)/GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) Vercirnon (GSK1605786...
BioCentury | Sep 23, 2013
Finance

Highlights of weekly biotech stock moves

...slipped $0.30 to $5.89 last week after GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) returned all rights to vercirnon...
BioCentury | Sep 23, 2013
Company News

ChemoCentryx, GlaxoSmithKline deal

...ChemoCentryx said GlaxoSmithKline returned all rights to vercirnon. In August, the pharma suspended the Phase III...
...2). ChemoCentryx said it will determine next steps for the program, including the development of vercirnon...
...dataset. Data from the Phase II/III PROTECT-1 trial to treat CD, showed that vercirnon (formerly Traficet-EN...
BioCentury | Sep 19, 2013
Company News

ChemoCentryx regains vercirnon rights from GSK

...ChemoCentryx Inc. (NASDAQ:CCXI) said GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) returned all rights to vercirnon. In August, the...
...ChemoCentryx said it will determine next steps for the program, including the development of vercirnon...
...dataset. Data from the Phase II/III PROTECT-1 trial to treat CD, showed that vercirnon (formerly Traficet-EN...
BioCentury | Sep 2, 2013
Finance

Highlights of weekly biotech stock moves

...29%) to $8.32 on Aug. 23 after partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said vercirnon ( GSK1605786...
...the CC chemokine receptor 9 ( CCR9 ) antagonist in the indication (see B2) . Vercirnon...
Items per page:
1 - 10 of 54